Scarica l'app Stockscreener
5.01
0.00%
0.00
Dopo l'orario di chiusura:
5.02
0.010
+0.20%
Precedente Chiudi:
$5.01
Aprire:
$4.93
Volume 24 ore:
20,246
Relative Volume:
0.41
Capitalizzazione di mercato:
$215.56M
Reddito:
$4.71M
Utile/perdita netta:
$-46.77M
Rapporto P/E:
-2.9836
EPS:
-1.6792
Flusso di cassa netto:
$-60.34M
1 W Prestazione:
+8.91%
1M Prestazione:
+1.21%
6M Prestazione:
-37.22%
1 anno Prestazione:
-48.72%
Intervallo 1D:
$4.81
$5.05
Intervallo di 1 settimana:
$4.45
$5.05
Portata 52W:
$4.345
$11.87
Nyxoah Sa Stock (NYXH) Company Profile
Nome
Nyxoah Sa
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NYXH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
5.01 | 215.56M | 4.71M | -46.77M | -60.34M | -1.6792 |
|
ISRG
Intuitive Surgical Inc
|
585.08 | 209.96B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
205.18 | 57.75B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.62 | 39.80B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
250.92 | 36.23B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
MDLN
Medline Inc
|
41.25 | 31.82B | 27.43B | 1.27B | 1.01B | 1.5829 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-31 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-19 | Iniziato | Robert W. Baird | Neutral |
| 2022-04-21 | Iniziato | Oppenheimer | Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Peer Perform |
| 2021-12-21 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Nyxoah Sa Borsa (NYXH) Ultime notizie
How Nyxoah SA (5YI) stock benefits from digital adoptionPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - ulpravda.ru
Aug Intraday: Is Nyxoah SA stock a good choice for value investors2025 Technical Overview & Community Consensus Trade Alerts - ulpravda.ru
Is Nyxoah SA stock a contrarian buyEarnings Recap Report & Real-Time Volume Surge Alerts - ulpravda.ru
Why Nyxoah SA stock is recommended by analysts2025 Pullback Review & Safe Entry Momentum Stock Tips - ulpravda.ru
Is Nyxoah SA stock a good choice for value investorsEarnings Risk Report & High Accuracy Trade Signal Alerts - ulpravda.ru
Nyxoah receives Medicare reimbursement increases for Genio - MSN
Nyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
PRN_FinancialWrapper | PR NewswireNyxoah to Present at the 44th Annual J.P. Morgan Healthcare Conference - FinancialContent
Sleep apnea therapy developer Nyxoah joins J.P. Morgan health event - Stock Titan
Contrasting Azenta (NASDAQ:AZTA) and Nyxoah (NASDAQ:NYXH) - Defense World
Baird Maintains Nyxoah SA(NYXH.US) With Hold Rating, Cuts Target Price to $5.87 - 富途牛牛
Nyxoah SA (NYXH) Stock Analysis: Exploring a 145.53% Potential Upside in the Medical Tech Sector - DirectorsTalk Interviews
Nyxoah announces commercial launch of Genio system in the Netherlands - MSN
Nyxoah launches Genio therapy in Netherlands and closes first €22.5 million tranche of convertible notes - MSN
Nyxoah price target lowered to EUR 5 from EUR 7 at Baird - MSN
Nyxoah Announces Issuance of First Tranche of Convertible Bonds - The Manila Times
Is Nyxoah SA stock positioned for digital transformationQuarterly Trade Review & Consistent Return Investment Signals - Улправда
Nyxoah Launches Genio Therapy in Netherlands and Closes First €22.5 Million Tranche of Convertible Notes - TipRanks
Earnings Recap: Is Nyxoah SA stock a good choice for value investorsJuly 2025 Highlights & Target Return Focused Picks - moha.gov.vn
Can Nyxoah SA stock deliver strong Q4 earningsQuarterly Growth Report & Smart Swing Trading Alerts - DonanımHaber
Is Nyxoah SA (5YI) stock undervalued historicallyJuly 2025 Sentiment & Daily Profit Maximizing Tips - DonanımHaber
How Nyxoah SA stock performs in high volatility markets2025 Historical Comparison & Expert Curated Trade Setups - ulpravda.ru
Nyxoah Launches New OSA Therapy | Patient-Centric Breakthrough - Precedence Research
Nyxoah Launches Genio Neurostimulator System in the Netherlands - marketscreener.com
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands - FinancialContent
Nyxoah (NASDAQ:NYXH) Trading Down 2.9%Here's What Happened - MarketBeat
Nyxoah (NASDAQ:NYXH) Trading Down 2.9% – Here’s What Happened - Defense World
Nyxoah announces shareholding changes as Robert Taub surpasses 10% threshold - MSN
Critical Analysis: Nyxoah (NASDAQ:NYXH) & P3 Health Partners (NASDAQ:PIII) - Defense World
Nyxoah Announces Shareholding Changes as Robert Taub Surpasses 10% Threshold - TipRanks
How Nyxoah SA (5YI) stock compares with tech leadersWeekly Stock Analysis & Community Verified Trade Signals - Newser
Will Nyxoah SA stock outperform international peersIPO Watch & Accurate Technical Buy Alerts - Newser
Is Nyxoah SA stock a buy for dividend growthJuly 2025 Levels & Risk Controlled Daily Plans - Newser
Will Nyxoah SA (5YI) stock remain on Wall Street radar2025 Institutional Moves & Reliable Breakout Forecasts - Newser
Nyxoah (NYXH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Publication relating to transparency notifications - marketscreener.com
Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System - MSN
Can Nyxoah SA (5YI) stock sustain institutional flowsJuly 2025 Intraday Action & Daily Chart Pattern Signals - Newser
What MACD trends signal for Nyxoah SA (5YI) stock2025 Dividend Review & Verified Entry Point Signals - Newser
Nyxoah’s Genio Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule - Sleep Review
Why The Narrative Around Nyxoah Is Shifting Amid Fresh Developments and Analyst Caution - Yahoo Finance
Nyxoah to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire
Nyxoah (NASDAQ: NYXH) schedules webcast fireside chat at Piper Sandler healthcare conference - Stock Titan
Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy - MSN
Nyxoah S.A. (NASDAQ:NYXH) Q3 2025 Earnings Call Transcript - MSN
Nyxoah’s Genio therapy gets significant 2026 Medicare reimbursement increases under final CMS rule - MSN
01 Communique (TSXV: ONE) teams with Turnium to expand IronCAP X quantum-safe email - Stock Titan
Nyxoah Sa Azioni (NYXH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.26%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):